Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...
Financial markets stay relatively quiet early Tuesday following Monday's choppy action. Investors await clarity on the next round of talks between the United States and Iran, while gearing up for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results